About ASLAN Pharmaceuticals Limited (ASLN) — Dividend Analysis 2026
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Is ASLN a good dividend investment in 2026?
ASLN offers a 333.33% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
ASLN DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your ASLN portfolio grows to $23346.46M vs $343.3K without reinvestment. This is the compound interest effect in action.
ASLN dividend growth history & forecast
ASLN has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 333.33%.
Company generates negative FCF ($-46M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.0B → -0.1B → -0.0B
15 / 30 pts
15/30
Net income grew in the latest year — positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 ASLN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ASLN.
Gross yield
333.33%
Tax rate
15.00%
After-tax yield
283.33%
Real yield (−CPI)
280.53%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
333.33%
330.53%
$33,333 / yr
🇺🇸 US Taxable (15%) ✓
15%
283.33%
280.53%
$28,333 / yr
🇺🇸 US Taxable (20%)
20%
266.66%
263.86%
$26,666 / yr
🇬🇧 UK ISA
0%
333.33%
330.53%
$33,333 / yr
🇬🇧 UK Taxable
8.75%
304.16%
301.36%
$30,416 / yr
🇨🇦 TFSA
0%
333.33%
330.53%
$33,333 / yr
🇨🇦 CA Taxable
25%
250.00%
247.20%
$25,000 / yr
🇦🇺 Super (pension)
15%
283.33%
280.53%
$28,333 / yr
🇦🇺 AU Taxable
30%
233.33%
230.53%
$23,333 / yr
🇩🇪 DE Taxable
26.375%
245.41%
242.61%
$24,541 / yr
🇫🇷 FR Taxable
30%
233.33%
230.53%
$23,333 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ASLN Income Goal & Break-Even
Dividend Break-Even
1yr
Years for dividends to fully repay your ASLN investment of $0.60/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$6851.18M
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$6851.18M
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in ASLN for:
Shares needed
14,118
Capital required
$8,471
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ASLN Dividend Payment Schedule
ASLN pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 ASLN vs Healthcare Benchmarks
How ASLN compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+330.53% vs sectorBetter
ASLN
333.33%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
ASLN
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
ASLN
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ASLN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ASLN Insider Activity
No recent SEC filings reported in the last 90 days.
🔬
Financial Health Scores
Altman Z-Score
-14.91
🔴 Distress Zone — elevated dividend cut risk
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
3/9
🔴 Weak fundamentals — dividend safety concern
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ASLN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →